Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Given Average Rating of “Buy” by Brokerages

Shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $31.62.

A number of research firms have issued reports on EIGR. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $28.00 target price on shares of Eiger Biopharmaceuticals in a report on Monday, November 11th. BidaskClub upgraded Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 30th. Zacks Investment Research cut Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, ValuEngine cut Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Eiger Biopharmaceuticals by 281.9% during the 2nd quarter. BlackRock Inc. now owns 1,729,161 shares of the biotechnology company’s stock worth $18,330,000 after buying an additional 1,276,408 shares during the last quarter. Cormorant Asset Management LP acquired a new position in shares of Eiger Biopharmaceuticals during the 2nd quarter worth about $12,190,000. Vanguard Group Inc. boosted its stake in shares of Eiger Biopharmaceuticals by 39.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,070,914 shares of the biotechnology company’s stock worth $11,352,000 after buying an additional 300,279 shares during the last quarter. Farallon Capital Management LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 2nd quarter worth about $10,600,000. Finally, Citadel Advisors LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 2nd quarter worth about $3,168,000. Institutional investors own 82.92% of the company’s stock.

NASDAQ:EIGR traded down $0.09 during trading hours on Monday, hitting $11.48. 111,300 shares of the stock were exchanged, compared to its average volume of 155,443. The company’s 50 day moving average is $10.61 and its two-hundred day moving average is $10.76. The company has a market capitalization of $285.12 million, a P/E ratio of -3.01 and a beta of 1.02. The company has a quick ratio of 6.83, a current ratio of 6.83 and a debt-to-equity ratio of 0.44. Eiger Biopharmaceuticals has a twelve month low of $8.40 and a twelve month high of $15.33.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.01). On average, equities research analysts expect that Eiger Biopharmaceuticals will post -2.49 EPS for the current year.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Article: How to Invest in the Dividend Aristocrat Index

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.